Search Results - "Roncolato, Felicia T."

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS) by Roncolato, Felicia T., Berton-Rigaud, Dominique, O'Connell, Rachel, Lanceley, Anne, Sehouli, Jalid, Buizen, Luke, Okamoto, Aikou, Aotani, Eriko, Lorusso, Domenica, Donnellan, Paul, Oza, Amit, Avall-Lundqvist, Elisabeth, Berek, Jonathan, Hilpert, Felix, Ledermann, Jonathan A., Kaminsky, Marie Christine, Stockler, Martin R., King, Madeleine T., Friedlander, Michael

“…Modified Glasgow Prognostic Score (mGPS) is predictive of survival in many advanced cancers, but has not been evaluated in recurrent ovarian cancer (ROC). The…”
Get full text

Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer by Campbell, Rachel, Costa, Daniel S.J., Stockler, Martin R., Lee, Yeh Chen, Ledermann, Jonathan A., Berton, Dominique, Sehouli, Jalid, Roncolato, Felicia T., Connell, Rachel O., Okamoto, Aikou, Bryce, Jane, Oza, Amit M., Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Lanceley, Anne, Joly, Florence, Hilpert, Felix, Feeney, Amanda, Kaminsky, Marie C., Diamante, Katrina, Friedlander, Michael L., King, Madeleine T.

“…The Measure of Ovarian Symptoms and Treatment (MOST) concerns is a validated patient-reported symptom assessment tool for assessing symptom benefit and adverse…”
Get full text

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study by Roncolato, Felicia T., Joly, Florence, O'Connell, Rachel, Lanceley, Anne, Hilpert, Felix, Buizen, Luke, Okamoto, Aikou, Aotani, Eriko, Pignata, Sandro, Donnellan, Paul, Oza, Amit, Avall‐Lundqvist, Elisabeth, Berek, Jonathan S., Heitz, Florian, Feeney, Amanda, Berton‐Rigaud, Dominique, Stockler, Martin R., King, Madeleine, Friedlander, Michael

“…Background Clinicians and patients often overestimate the benefits of chemotherapy, and overall survival (OS), in platinum resistant/refractory ovarian cancer…”
Get full text

Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice by Campbell, Rachel, King, Madeleine T, Stockler, Martin R, Lee, Yeh Chen, Roncolato, Felicia T, Friedlander, Michael L

“…Patient-reported outcomes (PROs) provide a valid, standardized way of assessing symptoms, adverse events and the subjective benefit of treatment from the…”
Get full text

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation by McBride, Sean Matthew, Niazi, Tamim, Williams, Scott, Davis, Ian D., Stockler, Martin R., Martin, Andrew James, Bracken, Karen, Roncolato, Felicia T., Horvath, Lisa, Sengupta, Shomik, Martin, Jarad, Lim, Tee, Hughes, Simon, McDermott, Raymond S., Catto, James W.F., Kelly, Paul J., Parulekar, Wendy R., Morgan, Scott Carlyle, Rendon, Ricardo A., Sweeney, Christopher

“…Abstract only TPS284 Background: Radiation therapy (RT), plus androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analog (LHRHA),…”
Get full text

Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy by Roncolato, F.T., Gibbs, E., Lee, C.K., Asher, R., Davies, L.C., Gebski, V.J., Friedlander, M., Hilpert, F., Wenzel, L., Stockler, M.R., King, M., Pujade-Lauraine, E.

“…Women with platinum-resistant ovarian cancer are a heterogeneous group whose median overall survival is 12 months. We hypothesized that their quality of life…”
Get full text

Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study by Lee, Yeh Chen, King, Madeleine T., O'Connell, Rachel L., Lanceley, Anne, Joly, Florence, Hilpert, Felix, Davis, Alison, Roncolato, Felicia T., Okamoto, Aikou, Bryce, Jane, Donnellan, Paul, Oza, Amit M., Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Ledermann, Jonathan A., Berton, Dominique, Sehouli, Jalid, Feeney, Amanda, Kaminsky, Marie-Christine, Diamante, Katrina, Stockler, Martin R., Friedlander, Michael L.

“…(Abstracted from Int J Gynecol Cancer 2022;32:761–768) Patients with recurrent ovarian cancer often experience a multitude of symptoms related to disease…”
Get full text

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303) by Williams, Scott G., Davis, Ian D., Sweeney, Christopher, Stockler, Martin R., Martin, Andrew James, Marchesin, Vittorio, Deignan, Olwyn, McDermott, Ray, Long, Anne Poh, Roncolato, Felicia T, Yip, Sonia, Hague, Wendy, Tu, Emily, Coskinas, Xanthi, Nguyen, Paul Linh

“…Abstract only…”
Get full text

Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304) by Davis, Ian D., Stockler, Martin R., Martin, Andrew James, Marchesin, Vittorio, Deignan, Olwyn, McDermott, Ray, Parulekar, Wendy R., North, Scott A., Graham, Barbara, Long, Anne Poh, Roncolato, Felicia T, Yip, Sonia, Hague, Wendy, Dazo, Carlo, Coskinas, Xanthi, Sweeney, Christopher

“…Abstract only…”
Get full text

Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy by Lee, Chee, Gibbs, Emma, Roncolato, Felicia T, Davies, Lucy Claire, Le Maignan, Christine, Meier, Werner, Arcusa Lanza, Maria Angeles, Rosenberg, Per, Marchetti, Claudia, Vergote, Ignace, Witteveen, Petronella, Bamias, Aristotelis, Serra, Sebastian, Provencal, Jocelyne, De Rauglaudre, Gaetan, Gebski, Val, Friedlander, Michael, Pujade-Lauraine, Eric

“…Abstract only…”
Get full text

Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS) by Roncolato, Felicia T, O'Connell, Rachel, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Pignata, Sandro, Donnellan, Paul P., Oza, Amit M., Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Sjoquist, Katrin Marie, Gillies, Kim, Butow, Phyllis, Stockler, Martin R., King, Madeleine Trudy, Friedlander, Michael

“…Abstract only…”
Get full text